Search Results
Your search for ,NOt matches 22378 pages
Showing 1301 - 1350Study Shows Potential Benefits of AI-Assisted Classification in HER2-Low and HER2-Ultralow Breast Cancer
With the approval of HER2-targeted antibody-drug conjugate options for treating patients with breast cancer across different HER2 expression levels, accurate assessment of HER2 expression has become more important than ever. And a recent study may provide a solution to the challenge of accurate...
Study Finds GLP-1RAs May Lower Risk of Obesity-Related Cancers vs DPP-4 Inhibitors in Adults With Diabetes and Obesity
Studies have shown that being overweight or having obesity increases the risk of developing more than a dozen cancers, including meningioma, multiple myeloma, esophageal, thyroid, breast, gallbladder, stomach, liver, pancreas, kidney, ovarian, uterus, and colorectal.1 The presence of excess body...
Maintenance Therapy With Lurbinectedin Plus Atezolizumab Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer
Maintenance treatment with the alkylating agent lurbinectedin plus the monoclonal antibody atezolizumab significantly improved both progression-free survival and overall survival compared with atezolizumab alone in patients with extensive-stage small cell lung cancer (SCLC), according to data...
Overall Survival Benefit Achieved With Inavolisib Plus Palbociclib and Fulvestrant in Advanced Breast Cancer
“Inavolisib plus palbociclib and fulvestrant significantly improved overall survival compared with placebo plus palbociclib/fulvestrant…. This is the first time overall survival has been significantly improved by a PI3K pathway–targeted drug,” said Nicholas Turner, MD, PhD, FRCP,FMedSci, who...
Use of Adjuvant Aspirin Reduces the Risk of Recurrence in PI3K-Mutated Colorectal Cancer
In the phase III ALASCCA trial, the use of adjuvant daily aspirin for 3 years reduced the risk of recurrence in colorectal cancer harboring PI3K pathway alterations by 51%, according to research in a Scandinavian population presented at the 2025 ASCO Gastrointestinal Cancers Symposium by Anna...
Localized Prostate Cancer: Long-Term Follow-up of Hypofractionated, Dose-Escalated vs Conventionally Fractionated RT
In a long-term follow-up of the phase III MD Anderson dose-escalated, hypofractionated prostate radiation study reported in the Journal of Clinical Oncology, Hassanzadeh et al compared hypofractionated intensity-modulated radiation therapy (HIMRT) vs conventionally fractionated intensity-modulated...
ACS CAN Statement on Federal Cuts to Cancer Research
On May 30, President Donald Trump released his final proposed budget for Fiscal Year 2026, which contains $4.531 billion for the National Cancer Institute (NCI). This represents a cut of almost $2.7 billion, or approximately 37.2%, from the current fiscal year. The following is a statement from...
Treatment for Intractable Cancer Pain Pioneered
A novel therapy based on the plant-derived molecule resiniferatoxin could be a safe and effective agent for patients with difficult-to-control cancer pain, according to a recent study published by Mannes et al in NEJM Evidence. Background Resiniferatoxin is derived from Euphorbia resinifera, a...
First-Line Nivolumab Plus Low-Dose Ipilimumab in MSI-H Advanced Gastric/GEJ Cancer
In a Japanese phase II study (NO LIMIT, WJOG13320G) reported in the Journal of Clinical Oncology, Kawakami et al evaluated whether first-line nivolumab plus low-dose ipilimumab showed activity in patients with microsatellite instability–high (MSI-H) advanced gastric/esophagogastric junction ...
FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer
On June 3, 2025, the U.S. Food and Drug Administration (FDA) approved darolutamide (Nubeqa) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). The oral androgen receptor inhibitor had previously been approved by the FDA in combination with docetaxel for mCSPC. Efficacy...
SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC
Although the SWOG S2302 Pragmatica-Lung trial did not achieve its primary endpoint of improved overall survival with the combination of ramucirumab and pembrolizumab compared with standard-of-care treatments for patients with stage IV or recurrent non–small cell lung cancer (NSCLC) who previously...
Preoperative THP Leads to pCR in Two-Thirds of Patients With Early-Stage HER2-Positive ER-Negative Breast Cancer
Patients with stage II and III (early-stage) HER2-positive breast cancer usually undergo preoperative therapy with multiagent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. A less intensive, reduced-chemotherapy treatment approach is currently being evaluated in the...
Ciltacabtagene Autoleucel Delivers Lasting Remissions in Relapsed or Refractory Multiple Myeloma
New long-term follow-up data from the phase Ib/II CARTITUDE-1 study demonstrated that one-third of patients in the study with relapsed or refractory multiple myeloma treated with the chimeric antigen receptor T-cell therapy ciltacabtagene autoleucel achieved progression-free survival of 5 years or...
Anti-Inflammatory Diet Could Benefit Survival Following Stage III Colorectal Cancer
Consuming an anti-inflammatory diet could improve posttreatment survival among patients with colorectal cancer compared with following a proinflammatory diet, according to new findings presented by Char et al at the 2025 ASCO Annual Meeting (Abstract LBA3509). The findings suggested that engaging...
EMR-Integrated Messaging Drastically Increases Cancer-Related Fertility Preservation Referrals
The integration of a "best practice advisory" alert into electronic medical record system regarding referrals for fertility preservation programs for young patients with cancer improved referrals to the Oncofertility program at Fox Chase Cancer Center by 450% over 6 months, according to findings...
Neoadjuvant Nivolumab and Chemotherapy Shows Significant OS Benefit at 5 Years in Resectable NSCLC
Neoadjuvant nivolumab plus chemotherapy significantly improved overall survival rates at 5 years compared with chemotherapy alone before surgery in patients with resectable non–small cell lung cancer (NSCLC), according to findings from the final analysis of the phase III CheckMate 816 trial. The...
Niraparib Plus Abiraterone in HRR-Mutant Metastatic Castration-Sensitive Prostate Cancer
Results from the international phase III AMPLITUDE clinical trial found that adding niraparib to abiraterone acetate plus prednisone (AAP) may help to slow cancer growth for people with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) gene...
Presurgical Combination Therapy Boosts Survival in Rare Thyroid Cancer, Study Finds
A presurgical combination therapy including pembrolizumab plus dabrafenib and trametinib significantly improved survival in patients with rare BRAF V600E–mutated anaplastic thyroid cancer compared with historical controls, according to new research from The University of Texas MD Anderson Cancer...
Dual Immunotherapy May Improve Progression-Free Survival in Advanced Squamous Cell Carcinoma
The combination of avelumab and cetuximab may improve progression-free survival in patients with advanced cutaneous squamous cell carcinoma compared with avelumab alone, according to recent findings presented by Zandberg et al at the 2025 ASCO Annual Meeting (Abstract 6002) and simultaneously...
Biomarkers May Shed Light on Treatment Options for High-Risk Prostate Cancer
Researchers may have uncovered factors contributing to poor outcomes among patients with prostate cancer, according to recent findings presented by Dall’Era et al at the 2025 ASCO Annual Meeting (Abstract 5104). The findings may lead to the development of novel targeted therapies, particularly in...
Potential New Standard of Care Emerges in Multiple Myeloma
A new four-drug combination appears to be effective and safe in patients with newly diagnosed multiple myeloma, according to data from the ADVANCE clinical trial conducted by investigators at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine. Presented ...
New Application May Help Caregivers of Patients Undergoing Bone Marrow Transplant
A novel application could help to improve the quality of life among caregivers of patients undergoing bone marrow transplant, according to recent findings presented by Jacobs et al at the 2025 ASCO Annual Meeting (Abstract 11000) and simultaneously published in the Journal of Clinical Oncology....
HER3-Targeted Antibody-Drug Conjugate for Treatment-Resistant Solid Tumors
Results from an international clinical trial demonstrated that DB-1310, a new antibody-drug conjugate, is showing early signs of effectiveness in patients with advanced solid tumors that have not responded to standard treatments, particularly those with EGFR-mutant non–small cell lung cancer...
Trastuzumab Deruxtecan/Pertuzumab Leads to Improved PFS for HER2-Positive Breast Cancer
Results from the phase III DESTINY-Breast09 clinical trial found that the combination of fam-trastuzumab deruxtecan-nxki (T-DXd) with pertuzumab may delay cancer growth for longer than the current standard of care in people with HER2-positive locally advanced or metastatic breast cancer. The...
ASCO 2025: Switching to Camizestrant After Detection of an ESR1 Mutation Improves Progression-Free Survival for Some Patients With Advanced Breast Cancer
Switching to treatment with camizestrant if an ESR1 mutation is detected during first-line treatment can help slow cancer growth for patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, according to findings from the phase III SERENA-6 clinical trial. The research is...
Impact of Empirical Dietary Inflammatory Pattern on Survival Outcomes in Patients With Stage III Colon Cancer
Greater intake of a proinflammatory dietary pattern may be linked to worse overall survival in patients with stage III colon cancer who have undergone curative-intent resection. Sara K. Char, MD, a clinical fellow at Dana-Farber Cancer Institute, Boston, presented the results of a prospective...
ASCO 2025: Perioperative Durvalumab Boosts FLOT Chemotherapy Benefit for Patients With Gastric Cancers
Results from an international phase III clinical trial found that treating patients with stage II, III, and IVA resectable gastric cancer and gastroesophageal junction (GEJ) cancer with perioperative durvalumab and FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) helped...
Nivolumab Added to Chemoradiotherapy Reduced Recurrence Risk in High-Risk Head and Neck Cancer
Adding the PD-1 inhibitor nivolumab to standard chemoradiotherapy after surgery significantly reduced recurrence rates for patients with locally advanced head and neck squamous cell carcinoma who are at high risk for recurrence, according to data presented at the 2025 ASCO Annual Meeting.1 At a...
Sacituzumab Govitecan and Pembrolizumab Improve Disease Control in Advanced PD-L1–Positive Triple-Negative Breast Cancer
Results from an international phase III clinical trial show that treatment with sacituzumab govitecan-hziy and pembrolizumab helps patients with unresectable, locally advanced or metastatic PD-L1–positive triple-negative breast cancer live longer without disease progression compared with...
Trastuzumab Deruxtecan Improves Survival Outcomes in Patients With HER2-Positive Gastric/GEJ Cancer in Second-Line Setting
The international phase III DESTINY-Gastric04 clinical trial found that second-line treatment with fam-trastuzumab deruxtecan-nxki can help people with advanced HER2-positive gastric cancers that have grown during first-line treatment live about 3 months longer. These findings further support the...
Molecular Assay Identifies Patients With Early NSCLC Likely to Benefit From Adjuvant Chemotherapy
Results from an international clinical trial show that a 14-gene molecular assay can help identify patients with early-stage nonsquamous non–small cell lung cancer (NSCLC) who could benefit from adjuvant chemotherapy after surgery. The research will be presented at the 2025 ASCO Annual Meeting...
Vepdegestrant Improves Progression-Free Survival in Select Patients With ESR1-Mutant Advanced Breast Cancer
Results from VERITAC-2 trial showed that the proteolysis-targeting chimera (PROTAC) vepdegestrant could extend progression-free survival for people with previously treated estrogen receptor (ER)-positive, HER2-negative advanced breast cancer with an ESR1 mutation. The research will be presented at...
Subset of Men With Rare Prostate Cancer May Benefit From Immunotherapy Added to Chemotherapy and Targeted Maintenance Therapy
Treatment options for aggressive-variant prostate cancer are limited, but a subset of patients have had promising long-term responses with a combination of carboplatin plus cabazitaxel chemotherapy, followed by PARP inhibitor maintenance. This novel combination treatment approach was the focus of a ...
Study Finds Novel Triplet Regimen Safe and Effective for Patients With Higher-Risk MDS and CMML
Patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) often experience temporary responses to current treatments, such as hypomethylating agents, which leads to an increased risk of the disease evolving to acute myeloid leukemia. In a phase II study,...
CAR T-Cell Therapy Continues to Demonstrate Activity in Advanced Clear Cell Renal Cell Carcinoma
For patients with metastatic clear cell renal cell carcinoma who did not benefit from checkpoint and tyrosine kinase inhibitors, limited alternative treatment options are available. ALLO-316 is a novel chimeric antigen receptor (CAR) T-cell therapy designed to recognize and kill cells expressing...
Castor Oil
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus...
Addition of Radium-223 to Stereotactic Ablative Radiotherapy in Oligometastatic Prostate Cancer
In a phase II trial (RAVENS) reported in the Journal of Clinical Oncology, Wang et al attempted to determine whether the addition of the bone metastasis–targeting agent radium-223 to stereotactic ablative radiotherapy improved progression-free survival as metastasis-directed therapy in patients...
FOLFIRINOX vs Gemcitabine in Nonresectable Locally Advanced Pancreatic Carcinoma
In a French phase III trial (NEOPAN) reported in the Journal of Clinical Oncology, Ducreux et al evaluated whether FOLFIRINOX (fluorouracil, oxaliplatin, and irinotecan) significantly improved progression-free survival vs gemcitabine in patients with locally advanced pancreatic carcinoma not...
Harm-Benefit Balance of Immune Checkpoint Inhibitor Treatment in Non–Small Cell Lung Cancer
In a study reported in JAMA Oncology, Heyward et al examined the harm-benefit balance of immune checkpoint inhibitor use across lines of treatment in non–small cell lung cancer (NSCLC). Study Details The retrospective cohort study, conducted in 2024, involved 2013 to 2019 Surveillance,...
Climate Change and Risk for Breast and Gynecologic Cancers
Climate change may be contributing to a small but notable increase in the incidence and mortality rates of breast, ovarian, endometrial, and cervical cancers in the Middle East and North Africa, according to a recent study published by Mataria and Chun in Frontiers in Public Health. Background...
How Family Adventures, Precision Oncology, and Living Purposefully Bring Balance to the Life of Charu Aggarwal, MD, MPH, FASCO
At just 5 years old, Charu Aggarwal, MD, MPH, FASCO, already knew that she wanted to be a physician when she grew up, although she can’t explain where the idea came from. She just knows the desire to help others was ingrained in her from a very early age. Growing up in New Delhi, India, where...
Physical Function Acts as Predictor of Survival for Daratumumab-Based Therapy in Multiple Myeloma
Patients with multiple myeloma who had lower physical function scores at the time of treatment initiation demonstrated a greater benefit to daratumumab treatment than those with higher physical function scores, according to the results of a study published in the European Journal of Haematology....
Enhanced CAR T-Cell Therapy for Lymphoma After Previous Failure on CAR T-Cell Therapy
In a single-center phase I trial reported in The New England Journal of Medicine, Svoboda et al assessed the safety, feasibility, and preliminary efficacy of an enhanced chimeric antigen receptor (CAR) T-cell therapy (huCART19-IL18) in patients with relapsed or refractory lymphoma after previous...
ESMO Releases Version 2.0 of the Magnitude of Clinical Benefit Scale
The European Society for Medical Oncology (ESMO) has announced the publication of the latest version of its scale that measures the clinical benefit of cancer treatments, the ESMO-MCBS (ESMO-Magnitude of Clinical Benefit Scale). The ESMO-MCBS was first introduced in 2015 and updated to version 1.1...
Mark Cuban Does It Again: Reshuffling the Deck of Front-Line CML Therapy
With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to an indolent one, associated with a near-normal life expectancy on optimal tyrosine kinase inhibitor...
DOJ Finds Federal Bureau of Prisons’ Colorectal Cancer Screening Practices Lacking
An evaluation by the Department of Justice Office of the Inspector General (DOJ OIG) of the Federal Bureau of Prisons’ (BOP) colorectal cancer screening practices for inmates and their clinical follow-up for positive screenings found several serious operational and managerial deficiencies...
Mortality Associated With Risk-Adapted Adjuvant Therapy in Postmenopausal Women With Early Breast Cancer
In a Danish Breast Cancer Group nationwide prospective cohort study reported in The Lancet Oncology, Jensen et al attempted to develop a prognostic standard mortality rate index to predict excess mortality based on risk-adapted adjuvant therapy in postmenopausal patients with early-stage breast...
I Have Stage IV Lung Cancer and Still Consider Myself the Luckiest Man in the World
Although I have spent the past 2 decades of my medical career as a primary care physician, educator, and researcher in conditions that disproportionately affect people of Asian descent, including lung cancer, I was still unprepared to hear the words “You have stage IV non–small cell lung...
Bringing Evidence-Based Integrative Medicine Into Everyday Oncology Practice
Despite the significant rise over the past 50 years in the use of evidence-based integrative medicine in conjunction with conventional cancer treatments—up from just 20% in the 1970s to about 80% in 20171—training opportunities in the fundamentals of this emerging field within the specialty of...
The Legal Impacts on Oncology Care of Prohibiting Diversity, Equity, and Inclusion Efforts
In January 2025, the Trump Administration issued executive orders asserting opposition to diversity, equity, and inclusion (DEI) programs on the federal level1,2 and rescinding Biden Administration orders that emphasized the importance of these efforts to promote equal opportunity across government ...
